Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Dasatinib Fails to Improve Outcomes in CBF-AML

2.

Millions of men could benefit from faster scan to diagnose prostate cancer

3.

WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction

4.

Adopted cancer cells and the effects of their presence.

5.

Gene therapy and chemotherapy may be combined in novel ways to treat bone cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot